中晚期腹腔肿瘤的腹腔化疗

Intraperitoneal chemotherapy of mid-late intraperitoneal tumor

目的 探讨腹腔化疗 (IPC)和腹腔热化疗 (IHC)对中、晚期腹腔恶性肿瘤 (MLMIT)治疗的机理、可行性、治疗方法和疗效。方法 静脉化疗 ,腹腔内置管埋药盒和腹腔临时穿刺置管 ,腹腔滴入抗癌药 14 0例病人。结果 1、2、3、4、5年生存率IPC组分别为 93.7%、4 6 .0 %、2 3.8%、9.5 %和 6 .3%。IHC组分别为 10 0 0 %、5 8.1%、37.2 %、2 5 .6 %和 16 .3%。而对照组 1年生存率仅为 2 .9%。对照组有效率为零。IPC组和IHC组疗效优于对照组 ,差异有显著性(P <0 .0 1)。结论 IPC和IHC治疗中晚期恶性肿瘤安全可靠 ,是提高疗效、防止复发或转移的有效疗法。

Objective To explore the therapeutic mechanism, feasibility, treatment and curative effect of the intraperitoneal chemotherapy (IPC) and intraperitoneal hyperthermic chemotherapy (IHC) for mid-late malignant intraperitoneal tumor (MLMIT).Methods A group of 140 patients who received anticancer drugs by intraoperative intraperitoneal catheterization, biological product and intravenous chemotherapy.Results The 1, 2, 3, 4 and 5-year survival rates of IPC group were 93.7%,46.0%, 23.8%,9.5% and 6.3% respectively; and the rates of IHC group were 100.0%, 58.1%, 37.2%, 25.6% and 16.3% respectively; The one year survival rate of the control group was 2.9%. The effective rate of the control group was zero. The curative effect of IPC and IHC was significant higher than that of the control group(P<0.01).Conclusions IPC and IHC is not only safe and reliable, but also curative for the treatment of mid-late intraperitoneal malignant tumors, which can prevent postoperative relapse or metastasis and provides significant long-term survival rates.